Patient characteristics
| Characteristic (n = 29) . | Data . |
|---|---|
| Sex, n (%) | |
| Female | 10 (34.5) |
| Male | 19 (65.5) |
| Age (mean), y | 20-66 (46.3) |
| Primary disease, n (%) | |
| AML | 13 (44.9) |
| ALL | 5 (17.3) |
| CML | 1 (3.4) |
| MDS | 6 (20.8) |
| HL | 1 (3.4) |
| MF | 1 (3.4) |
| NHL | 1 (3.4) |
| PMF | 1 (3.4) |
| Time to trial entry post HPCT (mean), y | 0.35-11.6 (1.89) |
| <6 mo, n (%) | 6 (20.7) |
| 6-12 mo, n (%) | 6 (20.7) |
| >12 mo, n (%) | 17 (58.6) |
| Source, n (%) | |
| SIB | 13 (45.0) |
| VUD | 16 (55.0) |
| Conditioning, n (%) | |
| Cy TBI | 12 (42.0) |
| Flu Mel | 17 (58.0) |
| Characteristic (n = 29) . | Data . |
|---|---|
| Sex, n (%) | |
| Female | 10 (34.5) |
| Male | 19 (65.5) |
| Age (mean), y | 20-66 (46.3) |
| Primary disease, n (%) | |
| AML | 13 (44.9) |
| ALL | 5 (17.3) |
| CML | 1 (3.4) |
| MDS | 6 (20.8) |
| HL | 1 (3.4) |
| MF | 1 (3.4) |
| NHL | 1 (3.4) |
| PMF | 1 (3.4) |
| Time to trial entry post HPCT (mean), y | 0.35-11.6 (1.89) |
| <6 mo, n (%) | 6 (20.7) |
| 6-12 mo, n (%) | 6 (20.7) |
| >12 mo, n (%) | 17 (58.6) |
| Source, n (%) | |
| SIB | 13 (45.0) |
| VUD | 16 (55.0) |
| Conditioning, n (%) | |
| Cy TBI | 12 (42.0) |
| Flu Mel | 17 (58.0) |
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; Cy TBI, cyclophosphamide plus total body irradiation; Flu Mel, fludarabine plus melphalan; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MF, mycosis fungoides; NHL, non-Hodgkin lymphoma; PMF, primary myelofibrosis; SIB, sibling; VUD, volunteer unrelated donor.